LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Cepheid Demonstrates Advantages of PCRplus Solution at AACC 2022

By LabMedica International staff writers
Posted on 26 Jul 2022
Print article
Image: PCRplus tests deliver rapid, accurate and actionable respiratory results (Photo courtesy of Cepheid)
Image: PCRplus tests deliver rapid, accurate and actionable respiratory results (Photo courtesy of Cepheid)

Cepheid (Sunnyvale, CA, USA) will be demonstrating the advantages of its PCRplus Solution at the 2022 AACC Clinical Lab Expo. PCRplus is an elevated PCR test category reserved for molecular diagnostic testing solutions that deliver uncompromised accuracy, speed, flexibility, simplicity, and exceptional test design expertise.

The PCRplus Solution comprises one platform and 22 IVD tests that combine accuracy, speed, flexibility, quality, and simplicity. Cepheid offers a growing portfolio of PCRplus respiratory tests that run on its 40,000 GeneXpert systems placed worldwide to deliver rapid, accurate, and actionable respiratory results. The GeneXpert System was built for simple, reference lab quality PCR testing – on location at medical centers and hospitals or closer to patient in health clinics and nursing homes. At the core of every GeneXpert System is the module (or testing bay) where a test cartridge is loaded onto the machine.

Cepheid’s line of GeneXpert Systems can be configured with a varying number of modules, or test bays, to meet the volume requirements of any setting. Smaller GeneXpert Systems are configured with two or four modules – meaning up to four different tests can be run at one time. The company’s largest GeneXpert System is configured with up to 80 modules – meaning as many as 80 tests can operate independently at any given time with a capacity of about 2,000 tests per day.

Cepheid offers CoV-2 tests that are designed with multiple gene targets to ensure comprehensive virus detection. This test design approach is used in all of Cepheid's Xpert CoV-2 tests to help guard against variants and ensure the test performance healthcare providers have come to rely on. The company has added the latest Xpert Xpress CoV-2plus test to Xpert Xpress CoV-2/Flu/RSV plus and others in its growing portfolio of PCRplus-based Xpert coronavirus tests.
 

Related Links:
Cepheid

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Sekisui Diagnostics UK Ltd.